Summary
Thirteen patients with AIDS related Kaposi's Sarcoma were entered on a phase II trial of ICRF-187, 1000 mg/m2 IV daily for 3 days every 3 weeks. Eight patients had received prior chemotherapy for AIDS-KS. Six patients had prior opportunistic infection. There were no complete responses; one partial response lasting six months was seen. Toxicity was significant, and of the first 5 patients treated, 3 out of 5 had grade III or IV neutropenia. Because of this, subsequent patients received 800 mg/m2 IV days 1–3 if previously untreated or 600 mg/m2 if previously treated. Overall 4 of 13 patients had Grade IV neutropenia and 5 of 13 had Grade III neutropenia. One patient had Grade IV thrombocytopenia. ICRF-187 at a daily × 3 schedule has some efficacy in the treatment of AIDS related KS, future trials should evaluate lower doses or alternate schedules of administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hymes KB, Cheung T, Greene JB: Kaposi's sarcoma in homosexual men: A report of eight cases. Lancet 11:598–600, 1981
Centers for Disease Control. Kaposi's sarcoma and pneumocytis pneumonia among homosexual men: New York City and California. MMWR 30:305–8, 1981
Centers of Infectious Disease Control, Centers for Disease Control. AIDS Weekly surveillance report. January, 1988
Creighton AM, Hellmann K, Whitecross S: Antitumor activity in a series of bisdiketopiperazines. Nature 222:384–385, 1969
Olweny CL, Sikyewunda W, Otim D: Further Experience with Razoxane (ICRF-159; — NSC-129943) in treating Kaposi's Sarcoma. Oncol 37(3): 174–176, 1980
Volberding P, Abrams D, Kaplan L, Conant M, Carr G: Therapy of AIDS-related Kaposi's Sarcoma (KS) with ICRF-159 (Abstr). Proc Am Soc Clin Oncol 4:4, 1985
Koeller J, Earhart R, Davis H: Phase I Trial of ICRF-187 by 48 hr continuous infusion. Cancer Treat Rep 65:459–463, 1981
Von Hoff D, Howser D, Lewis B, Holcenberg J, Weiss R, Young R: Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat Rep 65:249–252, 1981
Liesmann J, Belt R, Haas C, Hoogstraten B: Phase I evaluation of ICRF-187 in patients with advanced malignancy. Cancer 47:1959–1962, 1981
Krigel R, Laubenstein L, Muggia F: Kaposi's Sarcoma — A new staging classification. Cancer Treat Rep 67:531, 1983
Vogel C, Gorowski E, Davila E, Eisenberger M, Kosinski J, Agarwal RP, Savaray N: Phase I clinical trial and pharmacokinetics of weekly ICRF-187 infusion in patients with solid tumors. Invest New Drugs 5(2): 187–98, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chachoua, A., Green, M., Wernz, J. et al. Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's Sarcoma (AIDS-KS). Invest New Drugs 7, 327–331 (1989). https://doi.org/10.1007/BF00173762
Issue Date:
DOI: https://doi.org/10.1007/BF00173762